Anayat Ullah, Aliya Ali, Leena Medani, Jack Donati-Bourne Journal of Clinical Urology.2026;[Epub] CrossRef Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review Raafat Mady, Habib Tafazal, Haitham Soliman, Ayman Ramadan, Mohamed Hajaj Cureus.2026;[Epub] CrossRef Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer Giovanna Muscogiuri, Guendalina Del Vecchio, Luca Colangeli, Valeria Guglielmi, Paolo Sbraccia, Annamaria Colao Internal and Emergency Medicine.2026;[Epub] CrossRef Metabolism in PTEN hamartoma tumour syndrome Phil Ambery, Ralph Bgenholm, Thomas Pepper, Claire M
N.EnumulaV.RavaliN.KumarP
External resources Anorgasmia following initiation of GLP-1 agonist, PMC Case Report International Society for Sexual Medicine, GLP-1 Agonists and Sexuality GLP-1 Receptor Agonists, Compulsive Behavior, and Libido, PMC Research GLP-1 Agonist Weight Loss Medications and Sexual Desire, Journal of Sexual Medicine For researchers committed to understanding the full picture of how GLP-1 medications affect female health, SeekPeptides provides evidence-based protocols, comprehensive guides, and a community of knowledgeable researchers navigating these exact questions with the depth and nuance they deserve
The FDA has continued revising the label since: January 28, 2025 added acute kidney injury and severe gastrointestinal reaction warnings along with not recommended in patients with severe gastroparesis, and October 14, 2025 strengthened the pancreatitis warnings
[4] [6] However, for some patients, persistent nausea can significantly impact quality of life and treatment adherence
Experts say rapid, extreme weight loss can contribute to looser skin, particularly in curvier areas of the body
